Bland also held various sales and management positions in cardiovascular disease with Kos Pharmaceuticals before the company was sold to Abbott.
Bland received his B.S. and his M.B.A. degrees from The Citadel in Charleston, South Carolina.
“Scott adds a tremendous wealth of experience in cardiovascular disease management to our team at Berkeley HeartLab,” said Chris Hall, chief business officer of BHL. “We’ve experienced substantial growth and expansion at BHL, and as a result there’s a need to strengthen our commercial infrastructure. This new position goes a long way toward achieving this, and with a strong customer focus and a deep knowledge of the cardiovascular disease industry, we think Scott is well positioned to lead our sales efforts to deliver on our vision of personalizing disease management.”